ALPMF (Astellas Pharma) Total Liabilities: $10,941 Mil (As of Mar. 2026)

What is Astellas Pharma Total Liabilities?

Astellas Pharma ALPMF +10.51% 73 Total Liabilities is $10,941 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.67 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was $10,941 Mil.

Astellas Pharma's quarterly Total Liabilities declined from Sep. 2025 ($12,429.51 Mil) to Dec. 2025 ($11,795.17 Mil) and declined from Dec. 2025 ($11,795.17 Mil) to Mar. 2026 ($10,941.07 Mil).

Astellas Pharma's annual Total Liabilities declined from Mar. 2024 ($13,173.36 Mil) to Mar. 2025 ($12,252.24 Mil) and declined from Mar. 2025 ($12,252.24 Mil) to Mar. 2026 ($10,941.07 Mil).

Astellas Pharma Total Liabilities Related Terms

Astellas Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Total Liabilities Chart

Astellas Pharma Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Total Liabilities

Get a 7-Day Free Trial

7,354.58

7,096.61

13,173.36

12,252.24

10,941.07

Astellas Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															12,252.24	12,832.20	12,429.51	11,795.17	10,941.07

73GF Score

Astellas Pharma Inc ALPMF

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Astellas Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Astellas Pharma's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7678.222	+	(2016.603	+	1068.536
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	135.32	+	42.386)
	=	10,941

Total Liabilities	=	Total Assets (A: Mar. 2026 )	-	Total Equity (A: Mar. 2026 )
	=	22479.086	-	11538.019
	=	10,941

Astellas Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7678.222	+	(2016.603	+	1068.536
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	135.32	+	42.386)
	=	10,941

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	22479.086	-	11538.019
	=	10,941

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $10,941 Mil mean?

Astellas Pharma (ALPMF) has a Total Liabilities of $10,941 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Astellas Pharma and its competitors.

Is Astellas Pharma's Total Liabilities too high?

Astellas Pharma's current Total Liabilities is $10,941 Mil. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Astellas Pharma's Total Liabilities compare to LLY and JNJ?

Astellas Pharma's Total Liabilities of $10,941 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Astellas Pharma and its competitors. Astellas Pharma's current Total Liabilities is $10,941 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Astellas Pharma stock overvalued right now?

Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.67, compared to a current price of $14.20 — trading 3.2% below its estimated fair value. The current Total Liabilities is $10,941 Mil. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Total Liabilities is $10,941 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.20 is trading 3.2% below its estimated GF Value™ of $14.67. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

Total Liabilities: $10,941 Mil
GF Value™: $14.67 vs. price of $14.20 (3.2% below fair value)
GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSE:4568 TSE:4578 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4519 LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B AMGN GILD PFE BMY LSE:GSK

Other Exchanges ALPMY:USA 4503N:Mexico 4503:Japan YPH:Germany

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website https://www.astellas.com

Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

73GF Score

Get the complete analysis for ALPMF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.20

Price

$14.67

GF Value

View ALPMF Analysis

See Total Liabilities data for all stocks →